Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EWTX with free AI briefings, catalyst countdowns, and dilution alerts.

EWTX · Edgewise Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.7B Cash on Hand
86.6mo Cash Runway
16.3% Short Interest
$55.42 Analyst Target (12)
Follow EWTX by email Get an email when EWTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EWTX, unsubscribe in one click. Privacy

📣 What EWTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
EDG-15400 Heart Failure With Preserved Ejection Fraction Phase 2 · NCT07795814 Recruiting
Sevasemten Dose 5 Duchenne Muscular Dystrophy Phase 2 · NCT05540860 Active not recruiting
Sevasemten Dose 4 Duchenne Muscular Dystrophy Phase 2 · NCT05540860 Active not recruiting
EDG-7500 Hypertrophic Cardiomyopathy Phase 2 · NCT06347159 Active not recruiting
Sevasemten Dose 3 Duchenne Muscular Dystrophy Phase 2 · NCT06100887 Active not recruiting
Sevasemten Dose 2 Duchenne Muscular Dystrophy Phase 2 · NCT06100887 Active not recruiting
Sevasemten Becker Muscular Dystrophy Phase 2 · NCT06066580 Enrolling by invitation
Sevasemten Dose 1 Duchenne Muscular Dystrophy Phase 2 · NCT06100887 Active not recruiting
Verapamil Healthy Subjects Phase 1 · NCT06916897 Completed
[14C]-EDG-7500 Healthy Volunteer Phase 1 · NCT06738836 Completed
Radiolabeled EDG-5506 Suspension Healthy Volunteer Phase 1 · NCT05730842 Completed
Radiolabeled EDG-5506 Intravenous Healthy Volunteer Phase 1 · NCT05730842 Completed
EDG-5506 Healthy Volunteer Phase 1 · NCT05730842 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EWTX holds $1.7B in cash and short-term investments (as of Sep 30, 2026) and burns about $60.4M/quarter from operations, an estimated runway of 86.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EWTX files for a raise →

👥 Who Owns EWTX

Insiders 14.2% Institutions (327 holders) 85.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
ORBIMED ADVISORS LLC
Director, 10% owner
Insider 15,252,867 13.93% 2025-05-09
Paradigm BioCapital Advisors LP Institution (13G, 5%+) 10,215,455 9.33% 2026-06-30
RA Capital Management, L.P. Institution (13G, 5%+) 8,392,730 7.67% 2026-06-30
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 7,298,521 6.67% 2026-09-30
Blackrock Inc. Institution (13F) 7,274,226 6.64% 2026-09-30
Novo Holdings A/S Institution (13F) 5,350,000 4.89% 2026-09-30
Driehaus Capital Management, LLC Institution (13F) 4,401,906 4.02% 2026-09-30
Perceptive Advisors Llc Institution (13F) 4,138,282 3.78% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 3,930,716 3.59% 2026-09-30
Baker Bros. Advisors, LP Institution (13F) 3,701,719 3.38% 2026-09-30
Peter A. Thompson
Director, 10% owner · +46,377 options
Includes shares also reported by ORBIMED ADVISORS LLC, counted once
Insider 443,792 0.41% 2025-04-03
R Michael Carruthers
Chief Financial Officer · +373,581 options
Insider 86,162 0.08% 2025-08-12

Share count 109,482,763 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-10
Nofi Michael
Option exercise (M) 10,937 – 10,937
2026-11-10
filed 2026-11-10
Nofi Michael
Sale (S) 4,442 $45.43 6,495
2026-11-10
filed 2026-11-10
Nofi Michael
Option exercise (M) 10,937 – –
2026-10-01
filed 2026-10-02
Fox Jonathan C
Award (A) 308 – 25,141
2026-08-12
filed 2026-08-17
Russell Alan J
Option award (A) 65,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full EWTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EWTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.